LGVN
Longeveron Inc - Class A (LGVN)
Healthcare • NASDAQ • $0.85-0.77%
- Symbol
- LGVN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.85
- Daily Change
- -0.77%
- Market Cap
- $24.75M
- Trailing P/E
- N/A
- Forward P/E
- -0.55
- 52W High
- $1.80
- 52W Low
- $0.48
- Analyst Target
- $6.82
- Dividend Yield
- N/A
- Beta
- -0.32
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Company websiteResearch LGVN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.